Barclays’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.5M | Sell |
81,429
-19,169
| -19% | -$309K | ﹤0.01% | 2536 |
|
|
2026
Q1 | $1.97M | Sell |
100,598
-143,675
| -59% | -$4.27M | ﹤0.01% | 2362 |
|
|
2025
Q4 | $7.6M | Buy |
244,273
+36,027
| +17% | +$988K | ﹤0.01% | 1893 |
|
|
2025
Q3 | $4.49M | Sell |
208,246
-22,858
| -10% | -$412K | ﹤0.01% | 2292 |
|
|
2025
Q2 | $3.23M | Buy |
231,104
+107,041
| +86% | +$1.45M | ﹤0.01% | 2478 |
|
|
2025
Q1 | $1.67M | Sell |
124,063
-33,797
| -21% | -$576K | ﹤0.01% | 2763 |
|
|
2024
Q4 | $3.03M | Buy |
157,860
+32,463
| +26% | +$706K | ﹤0.01% | 2581 |
|
|
2024
Q3 | $2.85M | Buy |
125,397
+66,550
| +113% | +$1.09M | ﹤0.01% | 2561 |
|
|
2024
Q2 | $766K | Sell |
58,847
-65,301
| -53% | -$904K | ﹤0.01% | 2763 |
|
|
2024
Q1 | $2.17M | Sell |
124,148
-95,445
| -43% | -$1.85M | ﹤0.01% | 2487 |
|
|
2023
Q4 | $4.78M | Buy |
219,593
+88,036
| +67% | +$1.39M | ﹤0.01% | 2133 |
|
|
2023
Q3 | $2.02M | Sell |
131,557
-125,979
| -49% | -$2.4M | ﹤0.01% | 1895 |
|
|
2023
Q2 | $6.13M | Buy |
257,536
+141,393
| +122% | +$3.63M | ﹤0.01% | 1236 |
|
|
2023
Q1 | $2.95M | Buy |
116,143
+16,823
| +17% | +$539K | ﹤0.01% | 1913 |
|
|
2022
Q4 | $2.9M | Sell |
99,320
-554,431
| -85% | -$12.8M | ﹤0.01% | 1997 |
|
|
2022
Q3 | $13.4M | Buy |
653,751
+635,456
| +3,473% | +$11.4M | 0.01% | 750 |
|
|
2022
Q2 | $212K | Buy |
18,295
+1,295
| +8% | +$17.4K | ﹤0.01% | 3387 |
|
|
2022
Q1 | $314K | Buy |
+17,000
| New | +$327K | ﹤0.01% | 3184 |
|
|
2019
Q3 | – | Sell |
-30
| Closed | -$1K | – | 7162 |
|
|
2019
Q2 | $1K | Sell |
30
-460
| -94% | -$18.5K | ﹤0.01% | 6862 |
|
|
2019
Q1 | $20K | Buy |
490
+489
| +48,900% | +$22.1K | ﹤0.01% | 6364 |
|
|
2018
Q4 | $0 | Sell |
1
-689
| -100% | -$39.8K | ﹤0.01% | 7373 |
|
|
2018
Q3 | $57K | Buy |
690
+565
| +452% | +$53.3K | ﹤0.01% | 6004 |
|
|
2018
Q2 | $12K | Sell |
125
-261
| -68% | -$27.6K | ﹤0.01% | 6474 |
|
|
2018
Q1 | $41K | Buy |
386
+216
| +127% | +$23.5K | ﹤0.01% | 6037 |
|
|
2017
Q4 | $27K | Buy |
170
+151
| +795% | +$19.2K | ﹤0.01% | 6141 |
|
|
2017
Q3 | $3K | Sell |
19
-244
| -93% | -$41K | ﹤0.01% | 6611 |
|
|
2017
Q2 | $51K | Buy |
263
+128
| +95% | +$21.6K | ﹤0.01% | 5355 |
|
|
2017
Q1 | $25K | Buy |
+135
| New | +$23.3K | ﹤0.01% | 5709 |
|
|
2015
Q3 | – | Sell |
-280
| Closed | -$126K | – | 7077 |
|
|
2015
Q2 | $126K | Buy |
+280
| New | +$113K | ﹤0.01% | 4497 |
|
Other funds holding VRDN
BG
PBA
KCM
FFM
DTC
Barclays's VRDN Position: Q2 2026 in Review
Barclays reduced its Viridian Therapeutics (VRDN) stake by 19% in Q2 2026, selling an estimated $309K and leaving 81,429 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2536.
Barclays first reported a position in VRDN in Q2 2015 and has held it in 29 quarters since. The position peaked at $13.4M in Q3 2022. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.
- Barclays held 81,429 shares of Viridian Therapeutics worth $1.5M as of Q2 2026.
- Barclays sold 19,169 Viridian Therapeutics shares in Q2 2026, an estimated $309K.
- Viridian Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2536 holding.
- Barclays first reported a position in Viridian Therapeutics in Q2 2015 and has held it in 29 quarters since.
- Barclays's Viridian Therapeutics position peaked at $13.4M in Q3 2022.
- 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.